| Fallopian Tube Neoplasm studied in …STUDIED_INderived10 of 792show all (up to 200) |
|---|
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 792 trials mapped (198 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 792 trials mapped (198 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 792 trials mapped (198 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843303Phase 2 · not yet recruiting Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study · condition mapped ALIAS · 792 trials mapped (198 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped CURATED_BROADER · 792 trials mapped (198 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05257408Phase 3 · active not recruiting Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer · condition mapped ONTOLOGY_EXACT · 792 trials mapped (198 active) | — | — | Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04590326Phase 1/Phase 2 · recruiting A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab · condition mapped ALIAS · 792 trials mapped (198 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 792 trials mapped (198 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 792 trials mapped (198 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 792 trials mapped (198 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |